手握阿斯利康重磅交易，国产减肥药“黑马”冲击港交所

健识局10-14

一家手握重磅BD的生物医药企业，正在冲刺港股。10月8日，诚益生物向港交所提交上市申请。这家公司做口服小分子GLP-1减肥药，2023年11月授权给了阿斯利康，拿到首付款1.85亿美元，总里程碑付款最高达到18.25亿美元。国内开发GLP-1的企业不少，能拿到这样大笔金额BD的却不多。诚益生物的创始人和科学顾问都曾任职于礼来，有着丰富的代谢类药物研发经验。IPO前，诚益生物的估值已经接近5亿美元。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2575244159?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-14 20:19","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2575244159","market":"us","top_or_hot":-1,"title":"手握阿斯利康重磅交易，国产减肥药“黑马”冲击港交所","media":"健识局","content":"<div>\n<p>一家手握重磅BD的生物医药企业，正在冲刺港股。10月8日，诚益生物向港交所提交上市申请。这家公司做口服小分子GLP-1减肥药，2023年11月授权给了阿斯利康，拿到首付款1.85亿美元，总里程碑付款最高达到18.25亿美元。国内开发GLP-1的企业不少，能拿到这样大笔金额BD的却不多。诚益生物的创始人和科学顾问都曾任职于礼来，有着丰富的代谢类药物研发经验。IPO前，诚益生物的估值已经接近5亿美元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014210406a45fa2a5&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>手握阿斯利康重磅交易，国产减肥药“黑马”冲击港交所</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n手握阿斯利康重磅交易，国产减肥药“黑马”冲击港交所\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-14 20:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014210406a45fa2a5&s=b><strong>健识局</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一家手握重磅BD的生物医药企业，正在冲刺港股。10月8日，诚益生物向港交所提交上市申请。这家公司做口服小分子GLP-1减肥药，2023年11月授权给了阿斯利康，拿到首付款1.85亿美元，总里程碑付款最高达到18.25亿美元。国内开发GLP-1的企业不少，能拿到这样大笔金额BD的却不多。诚益生物的创始人和科学顾问都曾任职于礼来，有着丰富的代谢类药物研发经验。IPO前，诚益生物的估值已经接近5亿美元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014210406a45fa2a5&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014210406a45fa2a5&s=b","article_id":"2575244159","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014210406a45fa2a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2575244159","pubTimestamp":1760444373,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"一家手握重磅BD的生物医药企业，正在冲刺港股。10月8日，诚益生物向港交所提交上市申请。港交所上市环境更宽松，诚益生物赴港敲钟的进展显然就能更快。ECC5004有望成为同类最佳，并且是第二个在全球上市的口服小分子GLP-1受体激动剂。10月13日，石药集团的依达格鲁肽α注射液的新药上市申请已获得国家药监局受理，适应症为减重。诚益生物的品种还在研发之中，根据协议，阿斯利康会和诚益生物共同开发和商业化ECC5004。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01093":"石药集团","BK4516":"特朗普概念","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0385154629.USD":"贝莱德营养科学基金A2","BK4588":"碎股","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4581":"高盛持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","AZN":"阿斯利康","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1548497426.USD":"安联环球人工智能AT Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4599":"减肥药","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","03933":"联邦制药","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","01801":"信达生物","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4534":"瑞士信贷持仓","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0882574055.USD":"富达全球健康医疗A ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC"},"translate_title":"Holding AstraZeneca's blockbuster deal, the \"dark horse\" of domestic diet drugs hit the Hong Kong Stock Exchange","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9,"AZN":1.5,"01801":0.9,"03933":0.9},"content_text":"一家手握重磅BD的生物医药企业，正在冲刺港股。10月8日，诚益生物向港交所提交上市申请。这家公司做口服小分子GLP-1减肥药，2023年11月授权给了阿斯利康，拿到首付款1.85亿美元，总里程碑付款最高达到18.25亿美元。国内开发GLP-1的企业不少，能拿到这样大笔金额BD的却不多。诚益生物的创始人和科学顾问都曾任职于礼来，有着丰富的代谢类药物研发经验。IPO前，诚益生物的估值已经接近5亿美元。据多家行业媒体报道，诚益生物高管曾透露在美国、香港两地上市的计划。港交所上市环境更宽松，诚益生物赴港敲钟的进展显然就能更快。2024年来，在港股成功上市的GLP-1开发企业包括九源基因、派格生物、银诺医药等，股价表现都不错，派格生物比发行价已经翻了三倍。包括诚益生物在内，还有多家GLP-1企业都在抓紧机会赴港“上岸”。“超越”礼来诚益生物的管线设计很有特色。目前五条主要管线基本围绕在2型糖尿病、减重、代谢相关脂肪性肝炎等代谢类疾病，其中3项已经进入临床阶段，分别是GLP-1受体激动剂、THR-β激动剂和SSAO抑制剂。这几个品种相互之间都有联用设计，以最大化利用产品价值。如GLP-1与长效胰淀素、口服SSAO抑制剂，以及THR-β激动剂与GLP-1药物、口服SSAO抑制剂的联用，分别用于减重、MASH的治疗。临床前研究显示，THR-β激动剂两项联用方案均已显现出进一步的获益，在改善肝纤维化，减重增肌方面都有更好的效果。图源：招股说明书进展最快、最受关注的是口服GLP-1药物（ECC5004），在2023年被阿斯利康收入囊中。有业内人士分析，诚益生物的ECC5004是由礼来的口服小分子Orforglipron改良而来，两者结构很相似。诚益生物的首席执行官周敬业、首席科学官徐剑锋均来自于礼来中国研发中心，此前分别是礼来的化学部负责人和首席科学家，在糖尿病及其并发症方面，从筛选到靶点验证、临床开发等有着丰富的经验。根据招股说明书，ECC5004的分子设计成功克服了现有GLP-1受体激动剂疗法的关键限制，实现了高口服生物利用度，并且不用像别的药物一样有严格空腹用药等限制。美国一期临床试验显示，接受治疗的糖尿病患者在第28天达到了5.76%的减重效果，即一个月减轻了9.4斤的体重。ECC5004有望成为同类最佳，并且是第二个在全球上市的口服小分子GLP-1受体激动剂。阿斯利康表面是买了早期临床管线，实则是买下了一个药物的分子结构，目前正用它探索与阿斯利康自己的SGLT2、口服PCSK9抑制剂联用效果，分别用于糖尿病、慢性肾病、心力衰竭等疾病的治疗。唯快不破今年年内，已有联邦制药、翰森制药、石药集团等完成了各自GLP-1类药物的出海，交易总金额均在20亿美元的水平。比其他biotech更有优势的是，诚益生物很早就拿到了一大笔BD收入。2024年10月，ECC5004完成2b期临床试验的首位患者给药。加上首付款，2024年，诚益生物成功拿到2.21亿元的BD收入，且得益于与阿斯利康的合作，那一年诚益生物的研发支出降低了28%。需要注意的是，后期临床的开展会消耗大量的资金。今年上半年，诚益生物研发开支达到1573万美元，已与2024全年持平，公司也由盈转亏，亏损超2000万美元。控制支出是一方面，将产品推进上市也同样关键。在GLP-1的战场上，除了诺和诺德司美格鲁肽、礼来替尔泊肽两大霸主，信达生物的玛仕度肽也已上市，还有至少8款国产司美格鲁肽在排队上市、14款GLP-1创新药物在三期临床阶段，5款左右在上市申请阶段。10月13日，石药集团的依达格鲁肽α注射液的新药上市申请已获得国家药监局受理，适应症为减重。诚益生物的品种还在研发之中，根据协议，阿斯利康会和诚益生物共同开发和商业化ECC5004。诚益生物表示，公司目标是让ECC5004成为同类药物中首批进入三期临床的药物，预计全球2b期试验与中国1b期试验均在2025年第四季度完成。这么看来，诚益生物还能持续收到阿斯利康的里程碑付款，短期无忧，但GLP-1的战场已然白热化。撰稿 |杨曦霞编辑｜江芸 贾亭","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575244159","isCrawlerRequest":true}